CARET, the beta-carotene and retinol efficacy trial to prevent lung cancer in asbestos-exposed workers and in smokers.
CARET is a two-armed, double-blind, randomized chemo-prevention trial to test the hypothesis that oral administration of beta-carotene 30 mg/day plus retinyl palmitate 25,000 IU/day will decrease the incidence of lung cancer in high-risk populations: heavy smokers and asbestos-exposed workers who have smoked. The agents combine anti-oxidant and nuclear tumor suppressor mechanisms. Fastidious monitoring for possible side effects is facilitated by inclusion of a Vanguard population. As of 31 December 1990, 6,105 participants of the 18,000 needed have been randomized in the trial. Efficacy results are expected in 1999.
Omenn
G S
GS
Fred Hutchinson Cancer Research Center, Seattle, WA 98104.
Goodman
G
G
Grizzle
J
J
Thornquist
M
M
Rosenstock
L
L
Barnhart
S
S
Anderson
G
G
Balmes
J
J
Cherniack
M
M
Cone
J
J
D000368:Aged; D001194:Asbestos / Q000009:adverse effects*; D002338:Carotenoids / Q000627:therapeutic use*; D004311:Double-Blind Method; D004359:Drug Therapy, Combination; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008175:Lung Neoplasms / Q000209:etiology / Q000517:prevention & control*; D008297:Male; D008875:Middle Aged; D016273:Occupational Exposure; D012907:Smoking / Q000009:adverse effects*; D014801:Vitamin A / Q000627:therapeutic use*; D019207:beta Carotene
D019207:beta Carotene; D014801:Vitamin A; D001194:Asbestos; D002338:Carotenoids